Are you the publisher? Claim or contact us about this channel

Embed this content in your HTML


Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog

Channel Description:

Visit One News Page for Europe news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Europe news headlines.

older | 1 | .... | 1585 | 1586 | (Page 1587) | 1588 | 1589 | .... | 1652 | newer

    0 0

    Crystallography Times vol. 10, No. 12, focusing on single crystal X-ray diffraction, is available from Rigaku Oxford Diffraction on the company’s website.

    THE WOODLANDS, Texas (PRWEB) December 19, 2018

    The latest edition of Crystallography Times from Rigaku Corporation has been published and is now available on the company’s global website.
    Crystallography Times is a monthly electronic newsletter serving the X-ray analysis community, published by Rigaku Oxford Diffraction (ROD). It concentrates on single crystal X-ray diffraction and presents the latest news and crystallographic research.

    The “Crystallography in the News” feature assembles current global news and developments in the fields of small molecule and protein X-ray diffraction. Each month, it highlight the latest research findings and advancements.

    Featured news articles include reports about researchers from Charité – Universitätsmedizin Berlin, using X-ray crystallography, demonstrating - on a molecular level - how a specific protein allows light signals to be converted into cellular information.

    Another news item discusses how Berkeley Lab researchers, in collaboration with scientists from SLAC National Accelerator Laboratory and the Max Planck Institute, have demonstrated that fluctuation X-ray scattering is capable of capturing the behavior of biological systems in unprecedented detail.

    The Product Spotlight in the current issue features the Rigaku XtaLAB Synergy DW dual wavelength X-ray diffractometer with HPC X-ray detector. Combining the increased flux of a rotating anode X-ray source with the flexibility of two different wavelengths, this multi-functional single crystal X-ray diffractometer is ideal for laboratories exploring a wide range of research interests.

    This month’s “Lab in the Spotlight” section presents Rigaku’s own application laboratory in the Rigaku Europe SE office in Neu-Isenberg, Germany. The facility consolidates all Rigaku European application labs in one easy-to-access location.

    A selection of 19 recently published scientific papers, a schedule of upcoming events, a book review and two featured videos are also included. Crystallography Times is published monthly. Readers can subscribe to the newsletter or view the current issue online at

    About Rigaku Oxford Diffraction (ROD)
    ROD was formed as the global single crystal business unit of Rigaku Corporation after the acquisition of the former Oxford Diffraction organization from Agilent Technologies in 2015. ROD is a leader in the field of single crystal analysis, both in the field of chemical crystallography as well as well as macromolecular crystallography. Formed in 1951, Rigaku Corporation is a leading analytical instrumentation company based out of Tokyo, Japan.

    For further information, contact
    Michael Nelson
    Rigaku Global Marketing Group
    tel: +1. 512-225-1796 Reported by PRWeb 1 hour ago.

    0 0

    Dusk Network Offers a *Compliant, Scalable and Privacy-Oriented Protocol For Security Token Issuance. *The Dusk Standard Can be Used by Companies to Create Security Tokens on Top of Dusk BlockchainLUXEMBOURG, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Asset Management Fund Olymp Capital today announced an investment in Amsterdam-based Dusk Network, the first cryptocurrency protocol that satisfies the entire Security Token Offering (STO) regulatory framework on the blockchain at a fraction of the cost. Thus, the Dusk Network is aiming to become the “Ethereum network” of STOs, with Dusk Token used as the standard for STOs, in the same way Ether Tokens (ERC-20) are used for ICOs. Olymp Capital will work closely with Dusk Network to deliver STO value for clients.

    Dusk Network enables investors to exchange *data privately and transfer* ownership assets (e.g. security tokens). It implements a real-time payment channel (a pay-as-you-go model) and rapid peer-to-peer data communication. The company has developed a framework that appeals to traditional and institutional investors, who cannot invest easily due to legal structures, creating an opportunity for Dusk Network to become a favored destination for STOs, as a one-stop shop platform to issue security tokens, with easy and fully compliant onboarding. Dusk aims to create a viable security token market and bring together businesses, regulators, and financial institutions.

    As a part of its collaboration with Ethfinex, Dusk Network opens access for Ethfinex and Bitfinex users to a private sale. Dusk Tokens will be listed on both Exchanges (Bitfinex and Ethfinex).

    Co-founder and CEO of Olymp Capital, Christophe de Courson, said: “The Dusk Network team has created a technology that adapts uniquely to the needs of STO investors, and we see tremendous upside from their infrastructure.”

    Dusk Network marks Olymp Capital’s third investment, after and Yeay GmbH’s WOM Protocol. Each investment represents Olymp’s thesis in sustainable businesses; represents the first and largest Internet of Things (IoT) network of its kind; WOM is the first word-of-mouth marketing platform for reaching fans via cryptocurrency, and Dusk is the first protocol to satisfy the entire STO regulatory framework. Olymp seeks to offer a full product suite for its investors – whether in equity or not.

    Dusk Network maintains strong partnerships within the ecosystem: Blockventure coalition, Switcheo Network, GSR, and Blonde 2.0 – which should drive fast growth of its community.

    Jelle Pol, CEO of Dusk Network said: “Through its strategic investment in Dusk Network, Olymp Capital has taken a foundation position in shaping the future of Security Token markets – a widely anticipated new digital asset class.  We want to elevate the community around STOs, and Olymp Capital represents an investor that is steeped in cryptocurrency innovation, so we have a strong partner to help us realize our vision for this market.”

    *About Dusk Network*

    Dusk Network is the first cryptocurrency protocol that satisfies the entire Security Token Offering (STO) regulatory framework on the blockchain at a fraction of the cost. The company’s technology provides the first protocol that satisfies the entire STO regulatory framework on-chain, at a fraction of the cost, and is decentralized, automated, scalable, confidential and compliant. Dusk Network will list on both Ethfinex and Bitfinex. The company is headquartered in Amsterdam, the Netherlands. More information can be viewed at   

    *About Olymp Capital*
    Olymp Capital is the first asset management firm in Europe to cover all the blockchain and crypto asset classes ecosystem. The firm is headquartered in Luxembourg and is comprised of experts in traditional finance and the blockchain ecosystem. The fund accepts investment both in fiat and crypto currencies. For more information, visit

    EDITOR’S NOTE: If you would like a color photograph of Christophe de Courson, CEO of Olymp Capital; Jelle Pol, CEO of Dusk Network, or Olymp Capital or Dusk Network logo files, please contact Chris Pfaff on or +1-201-218-0262. Reported by GlobeNewswire 58 minutes ago.

    0 0

    DGAP-News: Adrenomed AG / Key word(s): Conference

    19.12.2018 / 09:00
    The issuer is solely responsible for the content of this announcement.

    *International Opinion Leaders Align on Value of Adrenomedullin as Therapeutical Target and Biomarker in Sepsis and Acute Heart Failure*

    *- For the second time, Adrenomed and sphingotec host international scientific symposium on vascular integrity in Berlin*

    *- Top-tier clinical scientists and key opinion leaders discuss potential of Adrenomedullin in diagnosis and treatment of acute heart failure and sepsis*

    *Hennigsdorf/Berlin* *(Germany), December 19, 2018* - The 2^nd scientific symposium "Endothelial Dysfunction - Adrenomedullin as a diagnostic and therapeutic target" was hosted by Adrenomed AG, the vascular integrity company, and by sphingotec GmbH, a diagnostic company leading in innovative biomarkers, in Berlin on December 18, 2018. International top-tier clinical scientists and key opinion leaders aligned on the concept of vascular integrity, endothelial barrier dysfunction and the role of Adrenomedullin as a diagnostic and therapeutic target in life-threating conditions such as septic shock and acute congestive heart failure. Adrenomed and sphingotec aim to fulfill unmet medical needs in particular in ICU (intensive care unit) and ED (emergency department) patients.

    Regulation of vascular integrity is a fundamental process for human physiology and pathology. Severe impairment of the endothelial barrier - presenting in porous, leaky blood vessels and resulting in tissue congestion and edema - drives conditions that are most threatening to life, such as septic shock and acute congestive heart failure.

    The circulating hormone Adrenomedullin is the key regulator of vascular integrity. Adrenomedullin is mainly expressed and secreted by vascular endothelial cells and is known for its vasodilatory activity in the interstitium resulting in decreased blood pressure. In the circulation, Adrenomedullin has vasoprotective effects by directly tightening the gaps between endothelial cells, and subsequently preventing vascular leakage.^[1]

    "We validated Adrenomedullin as therapeutic target and biomarker in analyses of over 20,000 well-defined patient samples. Rising plasma levels of biologically active Adrenomedullin (bio-ADM^(R)) clearly demonstrate a worsening of vascular integrity leading to shock or tissue congestion independent of any other comorbidity," explained Dr. Joachim Struck, Vice President Medical Affairs of sphingotec GmbH and added "With the biomarker sphingotest^(R) bio-ADM^(R), patients at risk of worsening conditions can be clearly identified and monitored during hospital stay."^[2], [3]

    Subsequently, for rescuing vascular function, Adrenomed develops the monoclonal antibody Adrecizumab. Adrecizumab binds specifically to biologically active Adrenomedullin in the plasma, thereby stabilizing the molecule in the circulation and increasing the plasma levels of Adrenomedullin, while keeping its functionality. It has been recently published that Adrecizumab thereby improves vascular barrier function and survival in rodent models of systemic inflammation and septic shock.^[4]

    "With a biomarker-drug combination utilizing bioactive Adrenomedullin as target and biomarker for patient stratification, we are developing a unique solution to rescue vascular integrity in life-threatening conditions such as sepsis, septic shock and acute heart failure and are therefore responding to a very high unmet medical need," said Dr. Andreas Bergmann, Chief Scientific Officer of Adrenomed AG and Chief Executive Officer of sphingotec GmbH.

    Adrecizumab is currently under clinical evaluation in the AdrenOSS-2 trial, a biomarker-guided, double-blind, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial in 300 septic shock patients preselected with high bio-ADM^(R) levels.

    Dr. Jens Zimmermann, Chief Medical Officer of Adrenomed AG, presented results from the randomized, double-blind, placebo-controlled Phase Ia and Phase Ib studies, that included a total of forty-eight healthy volunteers to evaluate escalating doses of Adrecizumab. Adrecizumab demonstrated an excellent safety profile in both studies. In addition, the Phase Ib study in systemic inflammation indicated dose-dependent beneficial effects of Adrecizumab on vascular integrity without affecting inflammatory parameters. Results of the Phase I trials were recently published in the British Journal of Clinical Pharmacology.^[5]

    To allow timely access to bio-ADM^(R) values in daily practice, sphingotec is currently developing a point-of-care solution on the recently acquired Nexus IB10 platform. The test will deliver results within 20 minutes from whole blood without any preparation time. The fully-automated platform is already placed in more than 1,000 intensive care units, emergency departments and doctors' offices in Europe and the Middle East and proved its applicability in routine. sphingotec's biomarkers penKid^(R) and bio-ADM^(R) will complement the standard-of-care portfolio to offer an all-around solution for diagnosis of life-threatening conditions such as septic shock and congestion in acute heart failure. Furthermore, bio-ADM^(R) is currently developed as a high-throughput solution on the automated VITROS^(R) platform from Ortho Clinical Diagnostics.

    *About Adrenomed*
    Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed's mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company's lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.

    *About sphingotec*
    sphingotec GmbH (Hennigsdorf, Germany) is developing and marketing innovative biomarkers penKid^(R) and bio-ADM^(R) for prediction, diagnosis and therapy monitoring of AKI, congestive heart failure and septic shock, as well as the Nexus IB10 POC testing immunoassay platform acquired from Samsung-subsidiary Nexus Dx Inc. in May 2018. The company, founded by Dr. Andreas Bergmann in 2002, in addition is developing a pipeline of novel biomarkers which can predict the risks of obesity, breast cancer and cardiovascular diseases.

    *Contact *

    *Adrenomed AG*
    Frauke Hein, Ph.D. (Chief Business Officer)
    phone: +49 (0)3302 2077814

    *sphingotec GmbH*
    Deborah Bergmann (Vice President Marketing)
    phone: +49 (0)3302 2056523

    *Media Inquires*

    *MC Services AG*
    Eva Bauer/Julia von Hummel
    phone: +49 (0)89 21022880

    ^[1] Geven C et al. Shock, 2018; 50(2):132-40.
    ^[2] Caironi P et al. Chest, 2017; 152(2):312-20.
    ^[3] Kremer D et al. Eur J Heart Fail, 2018; 20(9):1363-65.
    ^[4] Geven C et al. Shock, 2018; 50(6):648-54.
    ^[5] Geven C et al. Br J Clin Pharmacol, 2018; 84(9):2129-41.

    19.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at -------------------- Reported by EQS Group 59 minutes ago.

    0 0

    Ramirent Plc               Stock Exchange Release       19 December 2018 at 10:20 EET                                                             Ramirent Finland Ltd has today signed a long-term co-operation agreement with SRV Group Plc. As part of the arrangement, Ramirent has acquired SRV Kalusto Oy's entire share capital. SRV Kalusto has currently 33 employees and the debt free purchase price of the company is EUR 21 million.

    SRV Kalusto has been acting as an internal equipment rental company in the SRV Group covering approximately one fourth of SRV's equipment rentals and related services at the construction sites. The deal between Ramirent and SRV Group Plc covers significant share of SRV's annual equipment rentals. In 2017, the net sales of SRV Kalusto Oy amounted to approximately EUR 8 million.

    As part of the agreement, SRV Kalusto Oy's name changes to Rami Kalusto Oy.

    "In line with our strategy, Ramirent is seeking for profitable growth in our core equipment rental business. The today announced agreement perfectly supports our targets and strengthens our leading position in Finnish construction equipment rental market," says *Mikael Kämpe*, Managing Director of Ramirent Finland Ltd.

    *Further information:*
    Mikael Kämpe, Managing Director, Ramirent Finland Ltd, tel. +358 40 192 3535,
    Ilkka Pitkänen, CFO, SRV Group Plc, tel. +358 40 667 09 06,

    *RAMIRENT *is a leading service company offering equipment rental for construction and other industries. Our mission is to help our customers gear up on safety and efficiency by delivering great equipment and smooth service with a smile. We have 2,900 co-workers at 300 customer centers in northern and eastern Europe. In 2017, Ramirent Group sales reached a total of EUR 724 million. Ramirent is listed on NASDAQ Helsinki. *Ramirent - Gear Up. Equipment rental at your service*

    *SRV *is a bold developer and innovator in the construction industry. We want to offer the best customer experience as a constructor of urban city centres, while also being the most attractive employer in the industry. Our genuine cooperation and enthusiasm for our work comes across in every encounter. Established in 1987, we are a publicly listed company that operates in selected growth centres in Finland, Russia and Estonia. Our revenue in 2017 was over EUR 1.1 billion. Just over 1,000 people work for us and we also employ a network of almost 4,000 subcontractors in our projects. Reported by GlobeNewswire 39 minutes ago.

    0 0

    XCMG President Wang Min Joins Talk with U.S. CEOs and Former Senior Officials WASHINGTON, Dec. 19, 2018 /PRNewswire/ -- Wang Min, President and Chairman of XCMG, China's leading construction machinery manufacturer, who was a featured speaker at the eleventh annual U.S.-China CEO & Former Senior Officials' Dialogue which was hosted on December 4 in Washington D.C., shared XCMG's 22-year journey in the U.S. and the company's and his vision for future cooperation and development between the two nations.

    "Over the course of international development, XCMG hopes to further exchange and communicate with the American manufacturing industry and seek areas of cooperation and common interest. We are committed to growing with our American partners and are focused on bringing reliable, high-quality products to clients around the world together," commented Wang.

    As the first Chinese construction machinery manufacturer to enter the country, XCMG has deep roots in the U.S. market, which it began exploring in the 1980s. By 1996, after 10 years of extensive research, it established its first joint venture with a local U.S. company, starting bulk sales in the country.

    Since then, XCMG has attended CONEXPO-CON/AGG in Las Vegas eight times, ensuring that the voice of the Chinese manufacturing industry is heard on the world stage, and promoting XCMG's advanced and durable products to more clients in North America and around the world.

    In 2012, XCMG launched a more comprehensive program in the U.S. and started to invest significantly in talent and material resources, including the establishment of an R&D center. Today, teams of engineers and product designers from both countries work together to develop next-generation machinery for the North American market, and accumulative successes have been achieved in technology R&D, product localization and market immersion.

    XCMG's North American-edition loader, released in 2015, was the company's first high-end product created by American engineers. It's been a great success, having been sold in mature markets such as Australia and Europe.

    In addition, XCMG has also entered the U.S. equipment rental market, having recently signed a long-term contract to be the earthmoving equipment supplier to Ahern, the fourth-largest rental company in the U.S.

    *About XCMG*

    XCMG is a multinational heavy machinery manufacturing company with a history of 74 years. It currently ranks sixth in the world's construction machinery industry. The company exports to more than 182 countries and regions around the world.

    For more information, please visit:, or XCMG's pages on Facebook, Twitter, YouTube, LinkedIn and Instagram.


    View original content:

    Related Links : Reported by PR Newswire Asia 3 minutes ago.

    0 0

    IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB4000 *OXFORD, UK / ACCESSWIRE / December 19, 2018 /* IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare (''orphan'') and common neurodegenerative diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to IB4000 for the treatment of Niemman-Pick disease Type C (NPC), a rare, debilitating, inherited lysosomal storage disorder that predominately affects pediatric patients.

    This orphan designation provides a number of FDA regulatory benefits, such as a 25% tax credit for the costs of clinical development, a waiver for all prescription drug user fees at the time of marketing approval (approximately $2.5 Million dollars per indication), and 7 years' exclusivity in the US from the date of marketing authorization.

    ''We are pleased to receive orphan designation for IB4000, which for the first time may give NPC patients a therapeutic option for the chronic liver dysfunction associated with the disease'' said Dr. Frances Platt, Professor of Biochemistry and Pharmacology in the Department of Pharmacology at the University of Oxford.

    NPC affects 1:100,000 live births and is most commonly caused by dysfunction of the NPC1 protein leading to the accumulation of lipids in lysosomes, resulting in impaired cell function and cell death in various organs, leading to a spectrum of symptoms in NPC patients. The disease typically begins in early childhood and is chronic and progressive in nature; motor and cognitive symptoms become more disabling over the course of the disease, negatively impacting the quality of life. Currently, the average age of death for NPC patients is approximately 10 years, with half of the patients dying before the age of 12.5 years.

    IntraBio, with its collaborators, has evaluated the effect of IB4000 in pre-clinical and observational clinical studies in order to establish the potential therapeutic value and clinical utility of IB4000 in treating Niemann-Pick disease Type C (NPC). The company intends to continue investigating the compound for the treatment of rare, genetic diseases like NPC that have extremely high unmet medical needs because there exist no approved therapies available in this disease setting.

    *About IntraBio*

    IntraBio Inc. is a biopharmaceutical company with a late-stage drug pipeline including novel treatments for common and rare neurodegenerative diseases. IntraBio's platform results from decades of research and investment at premier universities and institutions worldwide. Its clinical programs leverage the expertise in lysosomal function and intracellular calcium signaling of its scientific founders from the University of Oxford and the University of Munich.

    IntraBio's management team and consultants have vast commercial experience and a successful track record of drug development in the USA and Europe. Together, IntraBio's team translates innovative scientific research in the fields of lysosomal biology, autophagy, and neurology into novel drugs for a broad spectrum of genetic and neurodegenerative diseases so to significantly improve the lives of patients and their families.

    IntraBio Inc. is a US corporation with its principal laboratories and offices in Oxford, United Kingdom.

    *For further information please contact:*

    Cass Fields

    *SOURCE:* IntraBio Inc.
    View source version on Reported by Accesswire 1 hour ago.

    0 0

    Suominen Corporation     Stock Exchange Release     19 December 2018 at 2.00 pm EET

    Petri Helsky appointed President & CEO of SuominenSuominen’s Board of Directors has appointed Mr. Petri Helsky as the new President & CEO of Suominen Corporation. Before joining Suominen, Helsky was the CEO of Metsä Tissue Corporation until September 2018. He starts as the President & CEO of Suominen on 7 January 2019.

    “Suominen has great growth opportunities ahead and the Board of Directors believes that Petri Helsky’s personal capabilities and fitting professional background make him an excellent choice to guide Suominen to profitable growth,” says Jan Johansson, Chair of Board of Directors.

    “Suominen is a globally leading company in the nonwovens industry and I see lots of potential in the company. In the past few years, Suominen has built its capabilities decisively and expectations for success are high. This is an exciting challenge and I am very happy to join Suominen,” says Petri Helsky.

    Helsky (born 1966) is Master of Science in Economics and in Engineering. Prior to working as the CEO of Metsä Tissue Corporation, Helsky was the President of Pulp & Paper segment and President of the Asia-Pacific Region and member of Management Board in Kemira Oyj. He has extensive experience from international management positions. Petri Helsky is also member of Board of Directors of Exel Composites Plc.

    Suominen Corporation
    Board of Directors

    *For additional information, please contact*

    Risto Anttonen
    Vice Chair of the Board of Directors
    tel. +358 50 597 8400

    *Suominen in brief

    *Suominen manufactures nonwovens as roll goods for wipes as well as for medical and hygiene products. The end products made of Suominen’s nonwovens – wet wipes, feminine care products and swabs, for instance – bring added value to the daily life of consumers worldwide. Suominen is the global market leader in nonwovens for wipes and employs over 650 people in Europe and in the Americas. Suominen’s net sales in 2017 amounted to EUR 426.0 million and comparable operating profit to EUR 15.0 million. The Suominen share (SUY1V) is listed in Nasdaq Helsinki Stock Exchange (Mid Cap). Read more at

    NASDAQ Helsinki
    Main media
      Reported by GlobeNewswire 1 hour ago.

    0 0

    Uponor Corporation     Managers’ transactions     19 December 2018     14:00 EET

    *Notification of transactions by managers and their closely associated persons*

    Notification under the EU Market Abuse Regulation, article 19

    *Person subject to the notification requirement*
    *Name*: Oras Invest Oy
    *Position*: Closely associated person

    *Person discharging managerial responsibilities in issuer*
    *Name*: Annika Paasikivi
    *Position*: Member of the Board of Directors / Deputy member

    *Initial Notification   *
    *Reference number:*  743700KA2GMSYJM3CM12_20181219112722_2
    *Issuer *
    *Name*: Uponor Oyj
    *LEI*: 743700KA2GMSYJM3CM12

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: UBS MTF (XUBS)
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 534 Unit price: 9.3025 EUR
    (2): Volume: 702 Unit price: 9.305 EUR
    (3): Volume: 400 Unit price: 9.2775 EUR

    Aggregated transactions
    Volume: 1,636 Volume weighted average price: 9.29746 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: POSIT (XPOS)
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 1,000 Unit price: 9.28 EUR
    (2): Volume: 1,000 Unit price: 9.18 EUR
    (3): Volume: 1,500 Unit price: 9.17 EUR
    (4): Volume: 800 Unit price: 9.16 EUR
    (5): Volume: 1,000 Unit price: 9.1325 EUR

    Aggregated transactions
    Volume: 5,300 Volume weighted average price: 9.18406 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: XPAC
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 500 Unit price: 9.3025 EUR
    (2): Volume: 1,000 Unit price: 9.295 EUR
    (3): Volume: 2,000 Unit price: 9.2675 EUR
    (4): Volume: 624 Unit price: 9.3 EUR
    (5): Volume: 825 Unit price: 9.195 EUR
    (6): Volume: 1,150 Unit price: 9.2075 EUR
    (7): Volume: 2,350 Unit price: 9.2525 EUR
    (8): Volume: 1,250 Unit price: 9.3 EUR
    (9): Volume: 4,000 Unit price: 9.1875 EUR
    (10): Volume: 5,000 Unit price: 9.155 EUR
    (11): Volume: 1,775 Unit price: 9.13 EUR
    (12): Volume: 6,785 Unit price: 9.13 EUR
    (13): Volume: 1,070 Unit price: 9.13 EUR

    Aggregated transactions
    Volume: 28,329 Volume weighted average price: 9.18755 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 1,485 Unit price: 9.305 EUR
    (2): Volume: 9 Unit price: 9.305 EUR
    (3): Volume: 115 Unit price: 9.28 EUR
    (4): Volume: 145 Unit price: 9.295 EUR
    (5): Volume: 144 Unit price: 9.31 EUR
    (6): Volume: 144 Unit price: 9.32 EUR
    (7): Volume: 58 Unit price: 9.32 EUR
    (8): Volume: 10 Unit price: 9.32 EUR
    (9): Volume: 6 Unit price: 9.325 EUR
    (10): Volume: 57 Unit price: 9.325 EUR
    (11): Volume: 200 Unit price: 9.325 EUR
    (12): Volume: 120 Unit price: 9.325 EUR
    (13): Volume: 15 Unit price: 9.325 EUR
    (14): Volume: 53 Unit price: 9.32 EUR
    (15): Volume: 314 Unit price: 9.32 EUR
    (16): Volume: 567 Unit price: 9.325 EUR
    (17): Volume: 246 Unit price: 9.3 EUR
    (18): Volume: 76 Unit price: 9.3 EUR
    (19): Volume: 66 Unit price: 9.3 EUR
    (20): Volume: 175 Unit price: 9.3 EUR
    (21): Volume: 489 Unit price: 9.3 EUR
    (22): Volume: 1 Unit price: 9.3 EUR
    (23): Volume: 152 Unit price: 9.29 EUR
    (24): Volume: 66 Unit price: 9.29 EUR
    (25): Volume: 67 Unit price: 9.29 EUR
    (26): Volume: 258 Unit price: 9.295 EUR
    (27): Volume: 9,600 Unit price: 9.25 EUR

    Aggregated transactions
    Volume: 14,638 Volume weighted average price: 9.26977 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 846 Unit price: 9.2025 EUR

    Aggregated transactions
    Volume: 846 Volume weighted average price: 9.2025 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: TRQM
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 484 Unit price: 9.305 EUR

    Aggregated transactions
    Volume: 484 Volume weighted average price: 9.305 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: JPSI
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 1,500 Unit price: 9.3025 EUR

    Aggregated transactions
    Volume: 1,500 Volume weighted average price: 9.3025 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: DHEL
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 888 Unit price: 9.285 EUR
    (2): Volume: 1,930 Unit price: 9.24 EUR
    (3): Volume: 4,500 Unit price: 9.2475 EUR

    Aggregated transactions
    Volume: 7,318 Volume weighted average price: 9.25007 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 230 Unit price: 9.32 EUR

    Aggregated transactions
    Volume: 230 Volume weighted average price: 9.32 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 876 Unit price: 9.3225 EUR
    (2): Volume: 400 Unit price: 9.295 EUR

    Aggregated transactions
    Volume: 1,276 Volume weighted average price: 9.31388 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: BATP
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 1,135 Unit price: 9.3175 EUR
    (2): Volume: 1,137 Unit price: 9.3 EUR
    (3): Volume: 242 Unit price: 9.3 EUR
    (4): Volume: 1,138 Unit price: 9.29 EUR

    Aggregated transactions
    Volume: 3,652 Volume weighted average price: 9.30232 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 41 Unit price: 9.28 EUR
    (2): Volume: 85 Unit price: 9.28 EUR
    (3): Volume: 35 Unit price: 9.28 EUR
    (4): Volume: 11 Unit price: 9.295 EUR
    (5): Volume: 24 Unit price: 9.295 EUR
    (6): Volume: 44 Unit price: 9.31 EUR
    (7): Volume: 43 Unit price: 9.325 EUR
    (8): Volume: 100 Unit price: 9.325 EUR
    (9): Volume: 100 Unit price: 9.325 EUR
    (10): Volume: 7 Unit price: 9.32 EUR
    (11): Volume: 53 Unit price: 9.32 EUR
    (12): Volume: 36 Unit price: 9.3 EUR
    (13): Volume: 50 Unit price: 9.3 EUR
    (14): Volume: 29 Unit price: 9.29 EUR
    (15): Volume: 28 Unit price: 9.29 EUR
    (16): Volume: 76 Unit price: 9.27 EUR

    Aggregated transactions
    Volume: 762 Volume weighted average price: 9.30193 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: BATD
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 908 Unit price: 9.32 EUR
    (2): Volume: 763 Unit price: 9.325 EUR
    (3): Volume: 763 Unit price: 9.325 EUR
    (4): Volume: 400 Unit price: 9.3 EUR
    (5): Volume: 588 Unit price: 9.3 EUR
    (6): Volume: 588 Unit price: 9.295 EUR
    (7): Volume: 400 Unit price: 9.2975 EUR
    (8): Volume: 1,290 Unit price: 9.265 EUR
    (9): Volume: 967 Unit price: 9.29 EUR
    (10): Volume: 1,060 Unit price: 9.265 EUR
    (11): Volume: 1,000 Unit price: 9.26 EUR
    (12): Volume: 1,000 Unit price: 9.26 EUR
    (13): Volume: 1,000 Unit price: 9.26 EUR
    (14): Volume: 906 Unit price: 9.1975 EUR
    (15): Volume: 929 Unit price: 9.235 EUR
    (16): Volume: 863 Unit price: 9.23 EUR

    Aggregated transactions
    Volume: 13,425 Volume weighted average price: 9.2722 EUR

    *Transaction details*

    Transaction date: 18.12.2018
    Venue: AQXE
    Instrument type: SHARE
    ISIN: FI0009002158
    Nature of the transaction: ACQUISITION

    (1): Volume: 263 Unit price: 9.325 EUR
    (2): Volume: 341 Unit price: 9.295 EUR

    Aggregated transactions
    Volume: 604 Volume weighted average price: 9.30806 EUR

    Uponor Corporation

    Reetta Härkki
    General Counsel
    Tel. +358 20 129 2835

    Nasdaq Helsinki


    *Uponor in brief*
    The year 2018 marks Uponor's 100-year anniversary. Our success is built on strong partnerships with our customers and stakeholders in the past, present and future.

    Uponor is a leading international systems and solutions provider for safe drinking water delivery, energy-efficient radiant heating and cooling and reliable infrastructure. The company serves a variety of building markets including residential, commercial, industrial and civil engineering. Uponor employs about 4,000 employees in 30 countries, mainly in Europe and North America. In 2017, Uponor's net sales totalled nearly €1.2 billion. Uponor is based in Finland and listed on Nasdaq Helsinki. Uponor builds on you - Reported by GlobeNewswire 1 hour ago.

    0 0

    The diplomatic cables also reveal Europe's anxiety about Trump, Russia and Iran - concludes the New York Times Reported by Haaretz 1 hour ago.

    0 0

    *Dengvaxia^® vaccine approved for prevention of dengue in Europe*

    *Paris, France - December 19, 2018* - The European Commission has granted marketing authorization for Dengvaxia^®, Sanofi's dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to approve use of the dengue vaccine in European endemic areas.

    Dengue fever is a mosquito-borne infection that people can get up to 4 times in a lifetime. Dengue is also known as 'break-bone fever' since it can cause debilitating disease marked by prolonged episodes of high fever and severe joint pain. An infection can progress unpredictably to a life-threatening form of the disease called dengue haemorrhagic fever that often requires hospitalized care. Today, there is no specific treatment available for dengue.

    Dengvaxia^® will be available in Europe to prevent dengue disease in individuals 9-45 years of age with a documented prior dengue infection and who are living in endemic areas.

    "In some of the European overseas territories where dengue recurs regularly, people who have had a dengue infection previously are at risk of being infected with the virus again," explains Dr. Su-Peing Ng, Global Medical Head at Sanofi Pasteur, the vaccine unit of Sanofi. "As the second infection with dengue tends to be more severe than the first, it is important to be able to offer these people a vaccine that could help protect them against subsequent dengue infections."

    According to the WHO, the global incidence of dengue has grown rapidly in recent decades and it now threatens half of the world's population living in 128 countries.^[i] Dengue is endemic in several European territories located in tropical and sub-tropical climates prone to outbreaks of the disease particularly during the rainy season.^[ii] Earlier this year, dengue outbreaks in La Reunion resulted in more than 6,000 people being made ill by the virus, which is spread by a day-biting mosquito that often lives in people's homes. During past outbreaks of dengue in Guadeloupe and Martinique, more than 40,000 people reportedly contracted the fever.^[iii]^,[iv]

    The dengue vaccine has been evaluated in studies involving more than 40,000 people from 15 countries with up to six years of follow-up from large-scale clinical safety and efficacy investigations.

    Dengvaxia^® is approved for use in several endemic countries in Latin America and Asia where reducing the human and economic burden of dengue is critical. The vaccine is currently under priority review by the US Food and Drug Administration (FDA) as it would be considered a significant medical advance in the prevention of dengue, which is considered an unmet medical need by the FDA.


    *About Sanofi

    Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
    With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

    Sanofi, Empowering Life


    Media Relations Contact
    *Laurence Bollack
    Tel.: +33 (0)1 53 77 46 46 *
    Investor Relations Contact
    *George Grofik
    Tel.: +33 (0)1 53 77 45 45

    *Sanofi Forward-Looking Statements*
    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, expectations for the transfer of our American Depositary Shares (ADS) listing and the stock exchange on which our ADSs will be listed, as well as those risks and uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements

    ^[i] Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6:e1760. doi:10.1371/journal.pntd.0001760.

    ^[ii] San Martín JL et al. The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome Reality. Am J Trop Med Hyg 2010; 82(1):128-35.

    ^[iii] L'Azou M et al. Dengue seroprevalence in the French West Indies: a prospective study in adult blood donors. Am J Trop Med Hyg, 2015; 92(6):1137-40



    · Press release (PDF).pdf Reported by GlobeNewswire 1 hour ago.

    0 0

    Italy and the EU just struck a deal, avoiding the start of a fresh crisis for Europe· Italy and the EU agree a deal on the country's budget, averting a long expected crisis in the eurozone. Stocks reacted positively to the announcement and the euro gained.
    · After weeks of wrangling, the two parties have agreed to allow Italy to run a budget deficit of 2.04% next year.
    · Italy had previously proposed increasing its deficit to 2.4%, which risked breaking spending rules.

    Italy and the European Union have finally agreed a deal that will allow Europe's fourth largest economy to avoid sanctions from Brussels over its government budget for next year, averting a potential crisis in the eurozone.

    Brussels and Rome had been at loggerheads over the Italian government's plans to increase both the debt and deficit in the country, pushing the deficit as high as 2.4% of gross domestic product over the coming years. Such proposals put Italy at risk of falling foul of EU limits on spending.

    After weeks of wrangling, the two parties have agreed to allow Italy to run a budget deficit of 2.04% next year, higher than a previously mandated limit, but well below the Italian government's initial proposal.

    The agreement will provide the "basis for balanced budgetary and economic policies in Italy," Valdis Dombrovskis, the EU's most senior official dealing with the euro and financial systems, said according to the Financial Times.

    However, Italy "urgently needs to restore confidence in its economy to ease financial conditions and support investment," he added.

    "Let’s be clear, the solution is not ideal."

    *Read more: 'The real concern is what comes next': Markets are mixed as investors shift focus to the last Fed meeting of 2018*

    The agreement means that Italy will no longer be subject to the so-called Excessive Deficit Procedure (EDP) — which has the power to fine countries within the eurozone who break spending rules within the bloc. Italy's entry into the EDP was set to be announced on Wednesday.

    Markets have reacted positively to the announcement with Italy's benchmark FTSE MIB trading more than 1.7% higher on the day. It had climbed on Wednesday morning as rumours surfaced that a deal would be struck. The euro is also higher against the dollar on the day, trading at €1.1402, a gain of 0.35%.

    *SEE ALSO: If you thought 2018 was bad for markets, a cocktail of fears is set to make 2019 even worse*

    Join the conversation about this story »

    NOW WATCH: The equity chief at $6.3 trillion BlackRock weighs in on the trade war, a possible recession, and offers her best investing advice for a tricky 2019 landscape Reported by Business Insider 1 hour ago.

    0 0

    On 7 December 2016, the European Network on Debt and Development (Eurodad) released a report entitled "Survival of the Richest: Europe's role in supporting an unjust global tax system 2016" which was produced by NGOs in countries across Europe. Reported by Mondaq 1 hour ago.

    0 0

    According to the report, the global service analytics market was valued USD 438 million in 2017 and is expected to reach around USD 1,202 million by 2024, at a CAGR approximately 13.70% from 2018 to 2024.

    New York, NY, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Service Analytics Market By Business Application (Customer Service Analytics, Field Service Analytics, and IT Service Analytics), By Component (Solution and Services), By Deployment Mode (On-Premises and Cloud), and By Vertical (Banking, Financial Services, and Insurance (BFSI), Energy and Utility, Government, Healthcare and Life Sciences, Retail and Wholesale, Manufacturing, Media and Entertainment, Transportation and Logistics, Travel and Hospitality, and Others): Global Industry Perspective, Comprehensive Analysis, And Forecast, 2017 – 2024”*. According to the report, the global service analytics market was valued USD 438 million in 2017 and is expected to reach around USD 1,202 million by 2024, at a CAGR approximately 13.70% from 2018 to 2024.

    Service analytics is known for creating smarter managers, productive agents, and importantly delighted customers. With service analytics solutions, it is easier to drill into customer’s profile, update case history, and directly collaborate with the team from the service cloud console.

    *Browse through 103 Tables & 41 Figures spread over 210 Pages and in-depth TOC on “Global Service Analytics Market: By Type, Size, Share, Technology, Trends, Applications, Analysis and Forecast, 2017 – 2024”.*

    *Request Free Sample Report of Global Service Analytics Market Report @ *

    The global service analytics market is likely to gain momentum in the future, as many business sectors are seeking to improve their businesses by moving from on-premises to cloud-based services. Changing the landscape of business intelligence and big data and the increase in social media awareness among consumers is anticipated to further drive the service analytics market. However, the lack of a skilled workforce, data security, and privacy concerns might hamper the service analytics market globally.

    The global service analytics market is divided based on business application, component, deployment mode, and vertical. The business application is classified into customer service analytics, field service analytics, and IT service analytics. By component, this market is bifurcated into solution and services. The solution segment is estimated to lead the market and the services segment is projected to grow at a faster rate over the forecast time period. The vertical segment includes banking, financial services, and insurance (BFSI), energy and utility, government, healthcare, and life sciences, retail and wholesale, manufacturing, media and entertainment, transportation and logistics, travel and hospitality, and others. The retail and wholesale industry is anticipated to hold a substantial in the future. Companies operating in the retail and wholesale industry depend on historical data to study customer buying behavior, which helps in better understanding the customers’ requirements. The service data generated helps in preventing future breakdowns. Moreover, the deployment of service analytics over the cloud helps in minimizing costs, providing scalability, improving agility, and overcoming challenges.

    *Download Free Report PDF Brochure: *

    The North American service analytics market is anticipated to grow due to the rising adoption of cloud solutions by the organizations to improve information governance over the estimated timeframe. The presence of prominent market players in the region helps in the creation and implementation of new technologies. The implementation is driven by the need to track data patterns, thereby scrutinizing the business performance. The U.S. is a major shareholder in the region, owing to the presence of eminent players, such as Oracle, Salesforce, ServiceNow, Tableau, and Microsoft, which offer service analytics software and services.

    Europe is projected to hold a considerable share in the global service analytics market, owing to the rising adoption of service analytics solutions in the retail and wholesale industry. The growth of service analytics market is also estimated to be driven by the escalating demand for Social, Mobile, Analytics and Cloud Technologies (SMACT) in the retail sector. Moreover, huge investments, rising adoption of cloud services, and growing entrepreneurship spirit are expected to positively influence the service analytics market in the upcoming years.

    Browse the full *"Service Analytics Market By Business Application (Customer Service Analytics, Field Service Analytics, and IT Service Analytics), By Component (Solution and Services), By Deployment Mode (On-Premises and Cloud), and By Vertical (Banking, Financial Services, and Insurance (BFSI), Energy and Utility, Government, Healthcare and Life Sciences, Retail and Wholesale, Manufacturing, Media and Entertainment, Transportation and Logistics, Travel and Hospitality, and Others): Global Industry Perspective, Comprehensive Analysis, And Forecast, 2017 – 2024"* Report At

    The Asia Pacific is estimated to be the fastest growing region due to its frequent investments in the research and development activities. The growing IT landscape, technological advancement in analytics, cloud, and business intelligence, and an increasing population are likely to further boost the service analytics market in the region. Moreover, the developing countries, such as India and China, are adopting service analytics solutions at a large scale owing to the rising demand for cost-effective data management software and services.

    The Middle Eastern and African region is expected to contribute substantially toward the service analytics market over the estimated time period. Business intelligence, big data, and analytics are increasingly being employed to develop smarter business model frameworks. Big data is used by regional organizations to analyze customer buying behavior and to make informed business decisions. Moreover, the region is also witnessing rapid growth in IoT, which is used by various business sectors, such as healthcare, and energy and utility. Currently, there are numerous organizations in the region deploying IoT to provide cutting-edge solutions, which, in turn, is anticipated to accelerate the service analytics market expansion in the region.

    *Inquire more about this report before purchase @ *

    Prominent players of the global service analytics market include Agile CRM, Aureus Analytics, BlueFletch, Centina Systems, ClickSoftware Technologies, Datahero, Inc., Field Squared, Helpshift, iCharts, Microsoft Corporation, Microstrategy Incorporated, Mobi, Numerify, Inc., Oracle, Paskon, Inc.,, Inc., SAP SE, SAS Institute, Servicenow, Inc., Sisense, and Tableau Software, among others.

    *Request customized copy of report @ *

    *This report segments the global service analytics market into:*

    *Global Service Analytics Market: By Business Application*

    · Customer Service Analytics
    · Field Service Analytics
    · IT Service Analytics

    *Global Service Analytics Market: By Component*

    · Solution
    · Services

    · Consulting Services
    · Managed Services
    · Support and Maintenance Services

    *Global Service Analytics Market: By Deployment Mode*

    · On-Premises
    · Cloud

    *Global Service Analytics Market: By Vertical*

    · Banking, Financial Services, and Insurance (BFSI)
    · Energy and Utility
    · Government
    · Healthcare and Life Sciences
    · Retail and Wholesale
    · Manufacturing
    · Media and Entertainment
    · Transportation and Logistics
    · Travel and Hospitality
    · Others

    *Global Service Analytics Market: By Region*

    · North America

    · The U.S.

    · Europe

    · UK
    · France
    · Germany

    · Asia Pacific

    · China
    · Japan
    · India

    · Latin America

    · Brazil

    · The Middle East and Africa

    *Related Reports:*

    · *Mobile Artificial Intelligence (AI) Market: *
    · *Blockchain Identity Management Market:*
    · *FinTech Blockchain Market:*
    · *Intelligent and Cognitive Radio* Market:
    · *Serverless Architecture Market: *                                       

    *About Us:*

    Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

    *Follow Us LinkedIn: *
    *Follow Us Twitter: *

    *Blog:* |

    *Contact Us:*

    Joel John
    244 Fifth Avenue, Suite N202
    New York, 10001, United States
    Tel: +49-322 210 92714
    USA/Canada Toll-Free No.1-855-465-4651


    *Blog:* Reported by GlobeNewswire 1 hour ago.

    0 0

    Italy budget deal struck with Europe after months-long row The agreement follows a high-profile diplomatic row that has lasted for months. Reported by BBC News 1 hour ago.

    0 0

    Tesla boss says Boring Company's Loop system can transport modified autonomous EVs at speeds of up to 150mph

    Tesla boss Elon Musk’s Boring Company has unveiled a prototype underground tunnel that it says can transport autonomous electric cars at speeds of up to 150mph.

    The one-mile test tunnel in Los Angeles has been constructed to show the feasibility of The Loop, which Musk said was the “future of mass transit”. 

    Electric cars are modified with special tracking wheel attachments, which allow the car to be attached to a track in the tunnel. The attachment is designed to keep the car stable while travelling at high speeds, guided by its own autonomous functions. It is not clear what 'level' of autonomy such cars will need to have to use the tunnel.

    The Boring Company has modified a number of Tesla Model X SUVs to test on the prototype tunnel. Musk says the system is currently capable of reaching speeds up to 110mph, but test runs during the launch event were limited to 50mph.

    While only cars from Musk’s Tesla firm has so far been used on the tunnel, the entrepreneur said that any electric car with full autonomous capability would be able to use the system.

    Musk said that each tunnel could eventually support up to 4000 cars per hour, with a number of extra cars circulating the system capable of picking up and dropping off pedestrians. 

    A number of reports from those who had test runs said the ride was bumpy, which Musk said was down to the short timescale to prepare the tunnel. He claimed the finished version would be “as smooth as glass.”

    He added that the smaller size of the tunnels – less than 14 feet in diameter – compared to those for underground train lines (around 28 feet) meant they were cheaper and quicker to produce. Musk added that he was also investing in developing boring machinery to improve speeds.

    While some transport planners have questioned the viability of the scheme, suggesting it would create bottlenecks at the entrance and exit points, Musk said the small size of such stations meant more could be installed than for a subway system. He added that, while pricing was not set, he was aiming to charge $1 (80p) per trip.

    The Loop is a separate project to the Hyperloop One scheme that Musk is also involved in. That concept uses a vacuum-sealed turbo to propel large autonomous pods at speeds above 600mph, the new project is designed to work with modified cars.

    *Read more*

    *Tesla Model 3 becomes EV with longest range in Europe*

    *Autocar reveals the tech secret behind the Tesla Model 3*

    *How the Hyperloop One could revolutionise the way we travel* Reported by Autocar 58 minutes ago.

    0 0

    Dublin, Dec. 19, 2018 (GLOBE NEWSWIRE) -- The "Global B2C E-Commerce Delivery 2018" report has been added to *'s* offering.*Enhancement coming in the delivery of online purchases says* *report*

    Global B2C E-Commerce Delivery 2018 includes projections about new technologies that will improve delivery of online purchases.*Delivery timeliness and cost are considered as part of the purchase package*

    As consumers research products and consider an online purchase, they look for free or low-cost delivery. Part of the research includes a perusal of comments regarding delivery in online reviews written by previous purchasers. The report includes a summary of a survey from last year in the USA that found that late delivery, high shipping costs, lost items and erroneous tracking information were among the main sources of dissatisfaction with buying over the Internet.

    *Online sellers look to innovative technology to improve the delivery experience for shoppers.*

    Online merchants have found it necessary to offer alternatives to satisfy consumer expectations of the delivery process. Tradition store-based merchants offer the click-&-collect for online purchases to reduce delivery time and costs, and online-only sellers have established lockers in public places or convenience stores. The report includes the projections that innovative technologies such as driverless vehicles, drones, and droids will be put in place by the end of the next decade.

    *Report Summary*The global fashion B2C E-Commerce market is forecasted to exceed half a trillion euros in sales by 2022, according to projections cited in the report. In terms of online penetration of total retail sales by 2022, more than one-third of clothing, accessories, and footwear spending is expected to occur online. The growth is driven by increasing number of online fashion shoppers who look for convenience, larger product selection, lower prices, convenient payment methods, online reviews and product ratings when purchasing clothing and accessories on the Internet.Clothing is one of the most popular product categories purchased by digital shoppers worldwide. Due to its huge population and the high fashion online shopper penetration, China is the largest online fashion retail market globally. Tmall and Taobao are the leading channels for buying apparel products in that country, the report reveals. The USA is in second place worldwide in online sales volume of fashion products. As of summer 2018, Amazon was the preferred pure online store for purchasing fashion items among pure online players and multi-channel retailers in the USA. The UK is the European leader in online apparel, footwear and accessories retail sales, with more than a half of adults purchasing these items online in 2017. was the most popular fashion E-Commerce website in the world in terms of the number of monthly visits. Russian-based online fashion retailer ranked second, followed by pure online players and store-based, in a ranking from 2018 cited in the report.The global online clothing market competition intensifies as Amazon has demonstrated a strong interest in the global expansion of the online fashion segment in recent years. In the growing competitive environment, omnichannel strategies have become vitally important for both online and store-based retailers of apparel. In the USA, the online shopping sites of store-based retailers Walmart, Kohl's and Macy's were among the top five destinations for online clothing shopping. On the other hand, European online fashion retailer Zalando began to expand an offline segment by opening several brick and mortar outlets in Germany.

    *Questions Answered in this Report*

    · How is the clothing B2C E-Commerce market developing around the world?
    · What is the B2C E-Commerce sales volume of clothing in various markets worldwide?
    · What is the percentage of online shoppers that purchase clothing in 30+ global markets?
    · What are the major trends in online shopping for clothing in the leading markets?
    · What sellers are the major players of the fashion E-Commerce retail in different countries?

    *Key Topics Covered:*1. Management Summary

    2. Global Developments3. Asia-Pacific4. Europe5. North America6. Latin America7. Middle East and Africa*Companies Mentioned *· 11Street Co. Ltd.
    · Amazon Inc.
    · Aras Kargo A.S.
    · BRT S.p.A.
    · DHL Worldwide Express
    · DPD GeoPost Deutschland GmbH
    · Deutsche Post AG
    · Gmarket Co Ltd.
    · Hermes Group Ltd.
    · JNE Enterprises Inc.
    · Kohl
    · Lazada Group SA
    · MNG Holding Co. Inc.
    · Macy
    · UPS International Inc.
    · Walmart
    · Yurtici Kargo
    · Zalando

    For more information about this report visit

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    Laura Wood, Senior Press Manager
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: E-Business Reported by GlobeNewswire 57 minutes ago.

    0 0

    NEW YORK and MELBOURNE, Australia, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that it has appointed Eric Strati, PhD, to the new position of Senior Vice President, Commercial. He will drive commercial launch activities of the Company’s lead cell therapy product candidate remestemcel-L in the United States and Europe for the treatment of steroid-refractory acute graft versus host disease (aGVHD). Mesoblast estimates the annual peak sales for aGVHD to be approximately $US700 million in the United States and EU5. Dr Strati said: “My first priority is to build a highly efficient and targeted field sales team to leverage existing relationships with transplant centers in the United States. Key to rapid market penetration will be engagement with insurers and other reimbursement agencies as well as management of the product distribution process.”

    Prior to joining Mesoblast in 2015, Dr Strati held various leadership roles in global pharmaceutical companies, most recently at Novartis where he was Executive Director, Managed Markets, and a key member of the successful launch teams for the blockbuster drugs Entresto^® in chronic heart failure and Cosentyx^® in moderate to severe psoriasis.

    Mesoblast’s recently-appointed United States-based Directors Shawn Cline Tomasello and Joe Swedish will provide guidance to the commercial team, leveraging their combined extensive expertise in product launches, commercialization, pricing and reimbursement. Ms Tomasello most recently was Chief Commercial Officer at Kite Pharma and Pharmacyclics, and President of the Americas, Hematology and Oncology at Celgene. Mr Swedish was most recently President and CEO at Anthem, America’s leading health benefits provider.

    Mesoblast Chief Executive Dr Silviu Itescu stated: “Eric is well equipped to lead and execute on our product commercialization strategy as we transition to a fully integrated commercial stage company.” 

    Mesoblast plans to submit a rolling Biologics License Application with the FDA for use of remestemcel-L in treating steroid-refractory aGVHD in children in early 2019. In order to make remestemcel-L available as soon as possible, Mesoblast will work diligently to provide all information required by the FDA. There are no FDA approved treatments for this disease with high mortality.
    Remestemcel-L is already sold in Japan by Mesoblast’s licensee, JCR Pharmaceuticals, under the registered trademark TEMCELL^® HS Inj. 

    *About Mesoblast*
    Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).

    *Forward-Looking Statements*
    This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

    CONTACT: For further information, please contact:

    Julie Meldrum
    Corporate Communications
    T: +61 3 9639 6036

    Schond Greenway
    Investor Relations
    T: +1 212 880 2060
    E: Reported by GlobeNewswire 57 minutes ago.

    0 0

    Asia Pacific Excluding Japan (APEJ) Region Expected to Register Robust Growth in Bulk Chemical Packaging Consumption

    VALLEY COTTAGE, N.Y. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- Future Market Insights (FMI) delivers key insights on the global bulk chemical packaging market in its published report titled “*Bulk Chemical Packaging Market: Global Industry Analysis 2013-2017* *and Opportunity Assessment 2018-2027*”. In terms of revenue, the global bulk chemical packaging market is estimated to grow at a CAGR of 6.8% during the forecast period, owing to numerous factors on which FMI sheds light in the bulk chemical packaging market report. The Asia Pacific bulk chemical packaging market is expected to remain in the leading position during the forecast period. Industrial bulk chemical packaging includes intermediate bulk containers (IBC), flexitanks, and drums.

    The global bulk chemical packaging market is experiencing growth due to an increase in demand from end-use applications such as consumer chemicals, specialty chemicals, basic inorganic chemicals, and polymers & petrochemicals.

    In this report, FMI has discussed individual strategies followed by the recent developments in the bulk chemical packaging product segments. FMI suggests that the growth in intercontinental trade of industrial chemicals is fuelling the demand for bulk chemical packaging. Adoption of industrial drums and IBCs as packaging solutions for industrial chemicals has increased particularly in the United States & China. Out of several product types, the drums segment is expected to witness maximum use of bulk chemical packaging. FMI study analyses the bulk chemical packaging market in several regions and focuses on the key dynamics affecting the bulk chemical packaging market globally.

    *Request a Sample Report with Table of Contents and Figures*:

    *Regional Outlook of the Global Bulk Chemical Packaging Market*

    The North American bulk chemical packaging market report includes a country-level analysis of the U.S. and Canadian markets. The U.S. bulk chemical packaging market is expected to dominate the regional market throughout the forecast period. The Latin American bulk chemical packaging market includes a country-level analysis of Brazil, Mexico, and Rest of Latin America. Brazil is expected to witness fast-paced growth, while Rest of Latin America is expected to be a prominent bulk chemical packaging market in terms of market value during the forecast period. In the European bulk chemical packaging market analysis, prominent countries such as Germany, the U.K., Spain, France, Italy, and Rest of Europe are analyzed. The bulk chemical packaging market in France is projected to grow at the highest CAGR among the countries in the European region. Germany and Italy are expected to be highly attractive bulk chemical packaging markets in terms of market value share. The Asia Pacific Excluding Japan (APEJ) bulk chemical packaging market includes a country-level analysis of China, India, Malaysia, Singapore, Australia, and Rest of APEJ. The Middle Eastern & African bulk chemical packaging market includes a country-level analysis of the GCC countries, South Africa, Israel, and Rest of MEA. In the MEA bulk chemical packaging market, South Africa is projected to expand at the highest CAGR during the forecast period while the GCC countries segment is the largest marketplace of bulk chemical packaging throughout the forecast period.    

    *Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you*:

    The manufacturers of bulk chemical packaging are likely to eye the lucrative regions of the Asia Pacific as well as the Middle East & African regions in the coming years. Growing demand from the chemical industry is the key driver for the growth of the global bulk chemical packaging market. The Asia Pacific Excluding Japan (APEJ) bulk chemical packaging market is expected to create the highest incremental $ opportunity during the forecast period and is expected to grow at a significant pace in the coming years. Revenue from the bulk chemical packaging market in North America is estimated to account for over 20.5% of the global bulk chemical packaging market revenue in 2018.

    *Buy this report: *

    *Key Players in the Global Bulk Chemical Packaging Market*

    Key players considered in this report on global bulk chemical packaging market include Grief Inc., C.L.Smith Company, Schutz Container Systems, Inc., Mauser Group B.V. Industrial Container Services (ICS), Sonoco Product Company , Three Rivers Packaging Inc., TPL Plastech Ltd., Milford Barrel Co. Inc., Enviro-Pak Inc., Orlando Drum & Container Corporation, Fibrestar Drums Limited, Great Western Containers Inc., Patrick J. Kelly Drums, Inc., International Paper Company, Berry Global Inc., Sealed Air Corporation, DS Smith Plc., Hoover Ferguson Group, and Synder Industries Inc.

    For more insights, write in to

    *Preview Analysis of Bulk Chemical Packaging Consumption - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2027: *

    *More from FMI’s **Packaging** Intelligence:*

    · *Time Temperature Indicator Labels Market* Segmentation By Product Type - Color (Only) Based, Irreversible, Reversible, Barcode Based; By Technology Type – Photochemical,Enzymatic,Microbiological,Diffusion,Polymer-based,Others; By End Use Type – Pharmaceuticals, Food & Beverages, Chemicals & Fertilizers & Others:

    · *Pre-Printed Tape Market* Segmented By printing technology - Lithography, Flexography, Digital printing, Screen printing, Others; By material - Polypropylene (PP), Polyethylene (PE), Polyvinyl Chloride (PVC), Aluminum and copper foils, Others; By adhesive type - Hot-Melt, Acrylic, Solvent-based, Water-based, Others; By application - Bundling, Carton Sealing, Tamper Evident Seals, Product and Company Identification, Other :

    · *Heat Sealing Tape Market* Segmented By adhesive type - hot melt, pressure sensitive, water activated and others; By tape type - waterproof tape, heat-resistant tape, antistatic tape, Freon-proof tape, moisture-proof tape, aseptic tape and others; By usage type - carton sealing, masking, bag sealing and others; By application - food products, healthcare products, industrial products and others :

    *About Us*

    Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

    *Browse More **Packaging Insights*

    *Contact Us*

    Mr. Sudip Saha
    Future Market Insights

    616 Corporate Way, Suite 2-9018,
    Valley Cottage, NY 10989,
    United States
    *T:* +1-347-918-3531
    *F*: +1-845-579-5705
    T (UK): + 44 (0) 20 7692 8790
    *Press Office*:
    *FMI Blog: *
    *Website*: Reported by GlobeNewswire 47 minutes ago.

    0 0

    EDMONTON, Alberta, Dec. 19, 2018 (GLOBE NEWSWIRE) -- *Radient Technologies Inc.* (“Radient” or the “Company”) (*TSX Venture: RTI; OTCQX: RDDTF*) is pleased to announce that it has now filed an additional 9 provisional patent applications with the United States Patent and Trademark Office (the “USPTO”), bringing the total number of patent applications filed by the Company in 2018 to 40. The inventions covered in these patent applications relate to methods and systems for improving the safety, potency, flavour, and experience of cannabinoid extracts used in the manufacturing of food & beverage products.Further Details: Patents for Innovating Cannabinoid-Infused Food & Beverage Manufacturing Processes

    These provisional patent applications provide methods that are expected to be critical in the cannabinoid-infused food and beverage industry. The methods relate to the measuring, dosing, and testing of cannabinoid additives used in food & beverage manufacturing processes. Because cannabinoids such as cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) are extracted from plant biomass, the ability to produce food and beverage products with consistent and measurable cannabinoid content and potency is highly desired by both customers and regulators.

    Several of these inventions provide novel solutions poised for widespread adoption in the flavouring of cannabinoid-infused food & beverage products. Traditionally, edible and drinkable cannabis products have been interlinked with flavours and aromas associated with the marijuana plant. There is a need in the market to meet customer demand for cannabinoid-infused food & beverage products with a variety of desirable flavours.

    Further, some of these provisional patent applications cover functional packaging elements for cannabinoid-infused food & beverage products that Radient’s extensive analysis indicates will be in line with the direction of the cannabis industry. These packaging elements are intended to provide additional safety measures and an improved user experience.

    These provisional applications were first filed in the USPTO to create a priority date and allow for future filings in other selected jurisdictions, as appropriate, including Canada and Europe.

    Dr. Steven Splinter, Founder and CTO of Radient, stated: “With nearly 20 years of experience in developing and manufacturing extracts for our customers, providing our solutions to the food & beverage sector of the cannabis industry is a natural extension of our core capabilities.”

    *About Radient* 
    Radient extracts natural compounds from a range of biological materials using microwave assisted processing (“MAP™”), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its 23,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, and personal care markets. Since 2016, Radient has expanded its offerings to enter the cannabinoids market utilizing its MAP™ platform to process and extract cannabinoids including cannabidiol and tetrahydrocannabinol from cannabis biomass. Visit  for more information.  

    SOURCE: Radient Technologies Inc.

    Denis Taschuk, Chief Executive Officer,,
    (780) 465-1318;  

    Mike Cabigon, Chief Operating Officer,,
    (780) 465-1318 

    Caitlin Cheadle, Director of Communications,

    *Forward Looking Information: *
    This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the Company’s ability to receive approval for patent applications; the Company’s ability to expand into the U.S.; the Company’s ability to expand its operations in Europe and Canada; the Company’s ability to grow its business in the cannabis sector and food and beverage industries; and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.


    0 0

    Strongbridge Used Portion of $145 Million Upfront Cash Payment from Novo Nordisk to Fully Repay Outstanding Debt

    DUBLIN, Ireland and TREVOSE, Pa., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the closing of the transaction with Novo Nordisk to transfer the rights to MACRILEN™ (macimorelin) in the United States and Canada. The terms of the transaction are as follows:· Strongbridge received a one-time upfront cash payment of $145 million, of which a portion was used to fully repay outstanding debt.
    · In addition, Novo Nordisk purchased 5.2 million ordinary shares of Strongbridge at a purchase price of $7.00 per share, resulting in gross proceeds of $36.7 million.
    · Strongbridge will also be entitled to receive tiered royalties related to the sales of MACRILEN through 2027.
    · Novo Nordisk will fund Strongbridge’s rare endocrine commercial field organization to promote MACRILEN in the U.S. for up to three years.

    “As we near the end of 2018, the completion of this transaction significantly strengthens our financial position, and in 2019, the Company will continue to be very focused on rapidly progressing RECORLEV™ (levoketoconazole) for the potential treatment of Cushing’s syndrome as well as driving the growth of KEVEYIS® (dichlorphenamide),” said Matthew Pauls, president and chief executive officer of Strongbridge Biopharma.
    *About Strongbridge Biopharma
    *Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

    *Forward-Looking Statements *
    This press release contains forward-looking statements within the meaning of the federal securities laws. The words "anticipate,""estimate,""expect,""intend,""may,""plan,""potential,""project,""target,""will,""would," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements of historical facts, contained in this press release, are forward-looking statements, including statements related to Strongbridge's strategy, plans, and objectives of management for future operations. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in such statements. Additional risks and uncertainties relating to Strongbridge and its business can be found under the heading “Risk Factors” in Strongbridge’s Annual Report on Form 10-K for the year ended December 31, 2017 and subsequent filings with the SEC. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. The forward-looking statements contained in this press release are made as of the date of this press release, and Strongbridge Biopharma does not assume any obligation to update any forward-looking statements except as required by applicable law.


    *Corporate and Media Relations*
    Elixir Health Public Relations
    Lindsay Rocco
    +1 862-596-1304

    *Investor Relations*
    The Trout Group
    Marcy Nanus
    +1 646-378-2927

    First House
    Geir Arne Drangeid
    +47 913 10 458

    900 Northbrook Drive
    Suite 200
    Trevose, PA 19053
    Tel. +1 610-254-9200
    Fax. +1 215-355-7389 Reported by GlobeNewswire 47 minutes ago.

older | 1 | .... | 1585 | 1586 | (Page 1587) | 1588 | 1589 | .... | 1652 | newer